Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19261796 | 0.92 | OPRM1 (0.53) | SLC6A3SLC6A4SLC6A2OPRM1NPC1 | |
| SCHEMBL3519831 | 0.87 | SLC6A3 (0.55) | SLC6A3SLC6A4SLC6A2OPRM1NPC1 | |
| SCHEMBL31441136 | 0.85 | OPRM1 (0.65) | SLC6A3SLC6A4SLC6A2OPRM1 | |
| SCHEMBL433782 | 0.85 | SLC6A4 (0.51) | SLC6A3SLC6A4SLC6A2OPRM1NPC1 | |
| SCHEMBL626042 | 0.85 | OPRM1 (0.65) | SLC6A3SLC6A4SLC6A2OPRM1 | |
| SCHEMBL7377089 | 0.83 | OPRM1 (0.67) | SLC6A3SLC6A4SLC6A2OPRM1MAP4K4 | |
| SCHEMBL625815 | 0.80 | SLC6A4 (0.45) | SLC6A3SLC6A4SLC6A2OPRM1NPC1 | |
| SCHEMBL1611 | 0.80 | OPRM1 (0.67) | SLC6A3SLC6A4SLC6A2OPRM1MAP4K4 | |
| SCHEMBL1836317 | 0.78 | OPRM1 (0.53) | SLC6A3SLC6A4SLC6A2OPRM1MAP4K4 | |
| SCHEMBL21874325 | 0.77 | KMT2A (0.50) | SLC6A3SLC6A4NPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2015-05-07 | — | — | US | disclosed |
| US-8877975-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| CN-101394847-A | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC (US) | 2009-03-25 | — | — | CN | disclosed |
| EP-1976513-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | Sepracor, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007081857-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.